Phase II Study to Evaluate Efficacy and Safety of Single Weekly Administration of Bortezomib in Newly Diagnosed Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Biomarker; Therapeutic Use
- 01 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 17 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.